The SELECT trial’s results, published in 2023, established something that the GLP-1 agonist’s mechanistic profile had long suggested but clinical evidence had not yet confirmed: semaglutide reduced major adverse cardiovascular events by twenty-one percent in patients with established cardiovascular disease and obesity but without diabetes. The magnitude of effect, achieved in a primary prevention population without a glucose-lowering mechanism as the operative pathway, reframed the GLP-1 class from metabolic drugs with cardiovascular benefits to cardiovascular drugs with metabolic benefits. The distinction is not semantic — it determines the addressable patient population, the coverage rationale, and the clinical positioning that will shape prescribing and access for the next decade.
The Mechanistic Breadth of GLP-1 Signaling
The GLP-1 receptor is expressed in tissues far beyond the pancreas and gut — in the brain, the heart, the kidneys, and the liver — which is why the pleiotropic effects of GLP-1 agonism keep accumulating in clinical trials studying diverse endpoints. The anti-inflammatory effects of GLP-1 receptor signaling in macrophages and endothelial cells may explain the cardiovascular risk reduction independent of weight loss. The receptor’s presence in dopaminergic reward circuits of the brain may explain the observations — still preliminary but widely reported — that patients on GLP-1 agonists experience reduced cravings not just for food but for alcohol, nicotine, and other addictive substances. These are not small secondary findings; they are signals pointing toward a drug class whose therapeutic scope may be substantially broader than its approved indications.
The neurological signals are particularly intriguing and clinically premature simultaneously. Preclinical evidence from animal models has documented GLP-1 receptor agonism’s neuroprotective effects — reduced amyloid accumulation, attenuated neuroinflammation, preserved dopaminergic neurons in Parkinson’s-relevant models. Human trials in Alzheimer’s disease and Parkinson’s disease are underway but not yet definitive. The risk of mapping animal model findings to human neurodegeneration is well established; the history of Alzheimer’s drug development is a cautionary tale about the distance between amyloid reduction in mice and clinical benefit in humans. GLP-1 agonists may prove the exception. They may also prove to have modest neurological effects that are clinically real but considerably smaller than the mechanistic excitement currently suggests.
The Optimization Boundary
The boundary between therapeutic use of GLP-1 agonists and metabolic optimization has already begun to blur in clinical practice, and the cultural phenomenon of semaglutide’s adoption by individuals without obesity or diabetes — people seeking modest weight reduction, enhanced metabolic efficiency, or the reported cognitive and satiety effects that patients describe in terms that go beyond simple hunger suppression — raises questions that neither the clinical trial framework nor the regulatory apparatus is well designed to address. The clinical trials that established GLP-1 efficacy enrolled patients with defined disease states. The drug’s pharmacology does not recognize the diagnostic threshold; the receptor is expressed and functional in individuals below the BMI cutoffs that define trial eligibility.
This creates a genuine policy and clinical management problem. Patients who are not classically obese but who are seeking metabolic optimization are accessing GLP-1 agonists primarily through compounding pharmacies and telehealth prescribers operating with limited clinical oversight. The FDA’s regulatory posture on compounded semaglutide has tightened as the branded shortage has eased, but the demand for optimization-oriented GLP-1 access has not dissipated proportionately. The clinical risks of GLP-1 agonism in non-obese individuals — muscle mass loss, nutritional deficiency, the still-incompletely-characterized effects on lean mass composition — are less well-studied than the risks in the trial populations. The optimization economy is running ahead of the safety evidence, as it has reliably done with every significant pharmacological innovation in the past three decades.
The Coverage and Access Paradox
While some individuals access GLP-1 agonists outside the insurance system for optimization purposes, many patients with clinically established obesity and significant cardiovascular risk are denied coverage by plans and PBMs that treat GLP-1 agonists as lifestyle drugs rather than cardiovascular risk reduction agents. The SELECT trial’s cardiovascular outcomes data — the strongest evidence base for any drug in the GLP-1 class — has not uniformly translated into coverage expansion for the cardiovascular indication. The drug that wealthy optimization enthusiasts can access through a telehealth prescription and credit card remains denied to Medicaid enrollees with Class III obesity and three cardiac risk factors. The distributional asymmetry of pharmaceutical innovation in America has rarely been more starkly illustrated.
